Renalytix (LON:RENX) Stock Price Down 5.9% – Here’s What Happened

Renalytix Plc (LON:RENX)’s share price was down 5.9% during mid-day trading on Thursday . The stock traded as low as GBX 1.70 and last traded at GBX 1.84. Approximately 4,189,669 shares were traded during mid-day trading, an increase of 288% from the average daily volume of 1,080,198 shares. The stock had previously closed at GBX 1.95.

Renalytix Price Performance

The company has a 50 day moving average price of GBX 2.80 and a 200-day moving average price of GBX 5.39. The company has a quick ratio of 2.42, a current ratio of 1.21 and a debt-to-equity ratio of -118.57. The company has a market cap of £7.99 million, a price-to-earnings ratio of -0.46 and a beta of 1.97.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).